ENVOYER

Serial Number 98376228
688

Registration Progress

Application Filed
Jan 25, 2024
Under Examination
Dec 24, 2024
Approved for Publication
Nov 12, 2024
Published for Opposition
Nov 12, 2024
Registered

Trademark Image

ENVOYER

Basic Information

Serial Number
98376228
Filing Date
January 25, 2024
Published for Opposition
November 12, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Dec 24, 2024
Application
Pending
Classes
005 042

Rights Holder

Envoya Inc.

03
Address
157 Winthrop Road
Brookline, MA 02445

Ownership History

Envoya Inc.

Original Applicant
03
Brookline, MA

Envoya Inc.

Owner at Publication
03
Brookline, MA

Legal Representation

Attorney
Susan G. L. Glovsky

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

20 events
Date Code Type Description Documents
Jun 24, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 15, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Dec 24, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Nov 12, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 12, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 23, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 1, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 20, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Sep 20, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Sep 20, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Sep 20, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Sep 18, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 18, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 18, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 28, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 28, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 28, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 21, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 30, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 25, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Gene therapy products, namely, non-lipid polymer based nanoparticles for gene therapy; gene therapy products, namely polymer-based nanoparticles for medical, veterinary and pharmaceutical purposes; nucleic acid-containing products, namely RNA and DNA, for medical or veterinary purposes; gene therapy products for the treatment of cancer, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, or inflammatory diseases or disorders, namely, non-viral vectors; nanoparticle products for medical or veterinary purposes, namely, non-viral vectors; microparticle products for medical or veterinary purposes, namely, non-viral microparticles; nanoparticles for medical or veterinary purposes, namely, stabilized non-lipid polymer based nanoparticles; microparticles for medical or veterinary purposes, namely, microparticles that facilitate the delivery of pharmaceutical preparations; nanoparticles that encapsulate a nucleic acid payload for delivery to a cell or tissue for medical or veterinary purposes; microparticles that encapsulate a nucleic acid payload for delivery to a cell or tissue for medical or veterinary purposes; nanoparticles that encapsulate nucleic acids, proteins, small molecules for medical or veterinary purposes; microparticles that encapsulate nucleic acids, proteins, small molecules for medical or veterinary purposes; nanoparticles that encapsulate nucleic acids for medical or veterinary purposes; nanoparticles that encapsulate cytotoxic payloads in cells for medical or veterinary purposes; microparticles that encapsulate cytotoxic payloads in cells for medical or veterinary purposes; diagnostic preparations and chemical and diagnostic reagents for clinical or medical laboratory use
Class 042
Pharmaceutical research and development; research and development services in the field of pharmaceuticals; gene therapy research and development services; research and development services relating to the delivery of RNA and DNA therapeutics to patients; research and development services in the field of nanoparticles and microparticles; research and development services in the field of nucleic acid-containing particles; research and development services in the field of nucleic acids, proteins, and small molecules delivery; Development of nucleic acids, namely RNA and DNA, for encapsulating nanoparticles for targeted delivery; Research services in the field of nanoparticle characteristics; Research services in the field of microparticle characteristics; research and development services in the field of pharmaceutical preparations for the treatment of disease or disorders; research and development services in the field of pharmaceutical preparations for the treatment of cancer, muscular dystrophy, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, inflammatory diseases or disorders, rare diseases; scientific and technological services, namely, scientific research, analysis, testing, treatment optimizations in the field of nucleic acids, proteins, and small molecules delivery to human cells; scientific and technological services, namely, scientific research, analysis, testing, treatment optimizations in the field of protein delivery to human cells; Scientific and technological services, namely, research and design relating to scientific and technological services in the field of nucleic acids, proteins, and small molecules therapeutics

Additional Information

Translation
The English translation of "ENVOYER" in the mark is "SEND".

Classification

International Classes
005 042